Antengene : RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Antengene Corporation Limited ᅃ೘ᔼᖹϞࠢʮ̡

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that, with effect from March 26, 2021:

• (1) Mr. Hu has resigned from his office as a non-executive director of the Company; and

• (2) Dr. Chen has been appointed as a non-executive director of the Company.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the "Board") of Antengene Corporation Limited (the "Company") announces that Mr. Xubo Hu ("Mr. Hu") has resigned from his office as a non-executive director of the Company with effect from March 26, 2021 to pursue other business and work commitments. After resignation, Mr. Hu no longer holds any position in the Group.

Mr. Hu has confirmed that (i) he has no disagreement with the Board; and (ii) there are no matters with respect to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited or the shareholders of the Company.

The Board expresses its appreciation to Mr. Hu for his contributions to the Board during his tenure of services with the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

In addition, the Board is pleased to announce that Dr. Kan Chen ("Dr. Chen") has been appointed as a non-executive director of the Company with effect from March 26, 2021.

The biographical details of Dr. Chen are set out below:

Dr. Kan Chen, aged 39, is currently serving as a Principal at Qiming Venture Partners ("Qiming"), focusing on healthcare investment. Dr. Chen joined Qiming in February 2016, had served as associate and vice president and was deeply involved in Qiming's investment of the Company's series A financing. Dr. Chen has been a director of Connect Biopharma Holdings Limited (a company listed on NASDAQ with stock code CNTB) since December 2020.

From November 2012 to September 2014, Dr. Chen has been the group leader of Jiangsu Hengrui Medicine Co., Ltd. From October 2014 to January 2016, he has been the senior scientist of Janssen, Pharmaceutical Companies of Johnson & Johnson.

Dr. Chen obtained his Bachelor's degree in biological science from Fudan University in June 2004. He obtained his Doctor of Philosophy degree in cell biology from Case Western Reserve University in January 2009 and finished his postdoctoral training in immunology at Harvard Medical School in October 2012.

Dr. Chen entered into a service contract with the Company which the initial term of his service contract shall be three years commencing on March 26, 2021 until terminated in accordance with the terms and conditions of the service contract or by either party giving to the other not less than one month's prior notice.

Dr. Chen will receive no remuneration as director's fee.

Save as disclosed above, Dr. Chen does not hold any other position with the Company or its subsidiaries, has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years prior to the date of his appointment and does not have other major appointments and professional qualifications.

Save as disclosed above, to the best knowledge of the Company, Dr. Chen does not have any relationship with any other director, senior management, substantial shareholder or controlling shareholder of the Company, and does not have any interests in the shares in the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) as at the date of this announcement.

Save as disclosed above, there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, nor are there any other matters, relating to the appointment of Dr. Chen that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Dr. Chen in joining the Company.

By Order of the Board Antengene Corporation Limited

Dr. Jay Mei Chairman

Hong Kong, March 25, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin and Mr. Yiteng Liu as executive directors; Mr. Xubo Hu, Mr. Zhen Li and Mr. Yanling Cao as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.